Navigation Links
Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
Date:9/20/2007

Agreement demonstrates broad potential use of Intellect's clinical

candidate

NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on the development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, and CHDI, Inc., a non-profit organization pursuing the discovery and development of drugs to prevent or slow the progression of Huntington disease (HD), announced today that they have entered into an agreement under which CHDI will assess Intellect's OXIGON(TM) as a potential therapy for Huntington disease. CHDI has access to a variety of relevant research tools, including in vitro and in vivo assays and animal models. Intellect has completed Phase I clinical trials for OXIGON(TM) in elderly healthy volunteers.

Dr. Daniel Chain, CEO and Chairman of Intellect, commented: "We are pleased that CHDI is evaluating whether OXIGON's method of action might extend to Huntington disease. OXIGON(TM) is planned to enter Phase II clinical trials in Alzheimer's patients in 2008. The data generated in the CHDI study could support proceeding with clinical trials in HD patients as well."

"We are intrigued by the properties of this compound, which has demonstrated neuroprotective effects in various animal models," said Robert Pacifici, CHDI's Chief Scientific Officer. "We are pleased to work with the Intellect team to evaluate the usefulness of OXIGON(TM) to treat HD."

About OXIGON(TM)

Intellect's lead drug candidate, OXIGON(TM), is a chemically synthesized form of a naturally occurring molecule that has unique neuroprotectant and antioxidant properties. OXIGON(TM) has been demonstrated to protect the brain from many potent neurotoxins in animals and also to block the formation of toxic aggregates that result from abnormal folding of proteins such as beta amyloid
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (Entereg/Entrareg)
6. M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
9. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
10. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
11. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... ALBANY, New York , September 2, 2014 ... market report published by Transparency Market Research "Latin ... and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility ... Telehealth and Telemedicine, Respiratory Therapy, Infusion Therapy and ... Share, Growth, Trends and Forecast, 2014 - 2020" ...
(Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11
... PediaVision today announced that Loma Linda University,s Vision ... of California to receive the revolutionary new vision ... of Ophthalmology is offering free vision screenings to ... of First 5 Riverside , which invests ...
... DURHAM, N.C., Sept. 29, 2011 CoLucid Pharmaceuticals, Inc., ... Chief Executive Officer, Thomas P. Mathers, will be making ... Conference at 9:35 – 10:00 a.m. on Tuesday, October ... Hotel in Tokyo, Japan. The partnering meeting is expected ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan 2
(Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... guide titled, “Is Group Therapy Right for Me?” The ... joining group therapy or counseling, in addition to common ... in group therapy improve not only from the interventions ... the group and receiving feedback from group members,” says ...
(Date:9/2/2014)... 2014 Friendship Village of Schaumburg ... “This creates a contemporary marketing presence and visually ... parent organization, Friendship Senior Options,” said Stephen A. ... “By changing the logo, we are making sure ... seniors and their families.” , Friendship Village is ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
(Date:9/2/2014)... WASHINGTON Patients who return to the emergency department within ... are anxious about their symptoms and have lost trust in ... results of a study published online today in Annals ... Department: The Patient Perspective" ). , "When asked ... reported feeling that their symptoms were too severe to wait ...
(Date:9/2/2014)... -- Two new studies further confirm the health benefits ... breast-fed have a lower risk of ear, throat and ... finds a similar trend when it comes to allergies. ... in the immediate newborn period," said Dr. Jennifer Wu, ... City. She was not involved in the new studies. ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... BALTIMORE, June 16 Lupin Pharmaceuticals, Inc. (LPI),announced ... the Company,s,Abbreviated New Drug Application (ANDA) for Escitalopram ... U.S. Food and Drug Administration (USFDA)., Lupin,s ... Laboratories, Lexapro(R) tablets, indicated for the treatment of,major ...
... Researchers at Ben-Gurion University of the Negev (BGU) in ... tested at a Washington, D.C. hospital, that enables doctors ... instead of touching a screen, keyboard or mouse which ... just released article. , The June article," A Gesture-based ...
... to injury-related deaths, the gap between black and white ... researchers at the Johns Hopkins Bloomberg School of Public ... injury-related deaths among blacks ages 15 to 24 decreased, ... published in the June, 2008, edition of Injury ...
... and PLM Based on Dassault Systemes, Newly,Introduced V6 Platform and ... ... ST. PAUL, Minnesota, June 16 Intercim LLC, a global,leader ... highly regulated industries and Dassault,Systemes (DS) (Nasdaq: DASTY; Euronext Paris: ...
... COLUMBIA, S.C., June 16 BlueCross BlueShield,of South ... of,the company,s health insurance plans that also adds ... options., "With increasing health care costs forcing ... dropping their insurance or not,picking it up to ...
... Coffee,s aroma kick-starts genes in the brain, Journal of ... a wake-up call to the brain? Or just smell its ... some of the first evidence that simply inhaling coffee aroma ... with laboratory rats, they found that coffee aroma orchestrates the ...
Cached Medicine News:Health News:Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets 2Health News:Gesture interface device developed by Ben-Gurion University of the Negev 2Health News:Racial disparities reduced in injury related mortality 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 3Health News:S.C. BlueCross Launches Less-Costly Plans Geared to Groups Seeking More Options 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 3Health News:American Chemical Society's Weekly PressPac: June 11, 2008 4Health News:American Chemical Society's Weekly PressPac: June 11, 2008 5Health News:American Chemical Society's Weekly PressPac: June 11, 2008 6Health News:American Chemical Society's Weekly PressPac: June 11, 2008 7Health News:American Chemical Society's Weekly PressPac: June 11, 2008 8
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: